JAK2 mutations and clinical practice in myeloproliferative neoplasms

Cancer Journal

Volumn 13, Issue 6, 2007, Pages 366-371

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Essential thrombocythemia; Exon 12; JAK2; JAK2 V617F; JAK2V617F; MPL; Mutation; Myelofibrosis; Myeloproliferative; Polycythemia

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BCR ABL PROTEIN; HYDROXYUREA; JANUS KINASE 2; RECOMBINANT ALPHA INTERFERON; THROMBOPOIETIN RECEPTOR; JAK2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

CANCER SCREENING; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; ERYTHROCYTOSIS; EXON; GENETIC SCREENING; HUMAN; LOW DRUG DOSE; MOLECULE; MUTATION; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; WORLD HEALTH ORGANIZATION; ANIMAL; FEMALE; GENETICS; MALE; SIGNAL TRANSDUCTION;

ANIMALS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MUTATION; MYELOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION;

EID: 39749130423     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318159467b     Document Type: Review

References (87)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-375.
2. Gilliland DG, Blanchard KL, Levy J, et al. Clonality in myeloprolifer-ative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci USA. 1991;88:6848-6852.
3. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA. 1967;58:1468-1471.
4. Barr RD, Fialkow PJ. Clonal origin of chronic myelocytic leukemia. N Engl J Med. 1973;289:307-309.
5. Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295:913- 916.
6. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63: 125-130.
7. Fialkow PJ, Denman AM, Jacobson RJ, et al. Chronic myelocytic leukemia: origin of some lymphocytes from leukemic stem cells. J Clin Invest. 1978;62:815-823.
8. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189-194.
9. Martin PJ, Najfeld V, Hansen JA, et al. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature. 1980;287:49-50.
10. Fialkow PJ, Faguet GB, Jacobson RJ, et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58:916-919.
11. Reeder TL, Bailey RJ, Dewald GW, et al. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101:1981-1983.
12. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. J Natl Cancer Inst. 1960;25:85-109.
13. Kelliher MA, McLaughlin J, Witte ON, et al. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ ABL. Proc Natl Acad Sci USA. 1990;87:6649-6653.
14. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelog-enous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
15. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990;9:1069-1078.
16. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle. 2007;6:550-566.
17. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
18. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387- 397.
19. Kralovics R, Passamonti F, Buser AS, et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
20. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
21. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007; 356:459-468.
22. Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycy-themia vera. Leukemia. 2007:21:1960-1963.
23. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
24. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472-3476.
25. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001; 411:355-365.
26. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000; 103:211-225.
27. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548-5557.
28. Foster DC, Sprecher CA, Grant FJ, et al. Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci USA. 1994;91:13023-13027.
29. Le Coniat M, Souyri M, Vigon I, et al. The human homolog of the myeloproliferative virus maps to chromosome band 1p34. Hum Genet. 1989;83:194-196.
30. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385-395.
31. Krempler A, Qi Y, Triplett AA, et al. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis. 2004;40:52-57.
32. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15:12) in a myeloid leukemia. Blood. 1997;90:2535-2540.
33. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278: 1309-1312.
34. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65:2662-2667.
35. Murati A, Gelsi-Boyer V, Adelaide J, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia. 2005;19:1692-1696.
36. Bousquet M, Quelen C, De Mas V, et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene. 2005;24:7248-7252.
37. Adelaide J, Perot C, Gelsi-Boyer V, et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia. 2006;20:536-537.
38. Griesinger F, Hennig H, Hillmer F, et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11. 2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer. 2005;44:329-333.
39. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209.
40. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106:2162-2168.
41. Melzner I, Weniger MA, Menz CK, et al. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia. 2006;20:157-158.
42. Lee JW, Soung YH, Kim SY, et al. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. Leuk Lymphoma. 2006;47:313-314.
43. Sulong S, Case M, Minto L, et al. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia. Br J Haematol. 2005;130:964-965.
44. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377-3379.
45. Lee JW, Soung YH, Kim SY, et al. Absence of JAK2 V617F mutation in gastric cancers. Acta Oncol. 2006;45:222-223.
46. Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene. 2006;25:1434-1436.
47. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920-2921.
48. V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol. 2005;131:166-171.
49. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005;106:3374-3376.
50. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera - an unrecognized diagnosis. Am J Med. 1997;102:14-20.
51. Berlin NI. Diagnosis and classification of the polycythemias. Semin. Hematol. 1975;12:339-351.
52. Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2001:17-44.
53. Verstovsek S, Silver RT, Cross NC, et al. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia. 2006; 20:2067.
54. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110: 1092-1097.
55. Tefferi A, Pardanani A. Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. Mayo Clin Proc. 2007;82:599-604.
56. Tefferi A. Jak2 mutations in polycythemia vera-molecular mechanisms and clinical applications. N Engl J Med. 2007;356:444-445.
57. Tefferi A, Vardiman JW. The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol. 2007;14:115-122.
58. Thiele J, Kvasnicka HM, Zankovich R, et al. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica. 2001;86:368-374.
59. Tefferi A, Strand JJ, Lasho TL, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia. 2007;21: 2074-2075.
60. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007; 109:2279-2284.
61. Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006;106:631-635.
62. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005;131:320-328.
63. V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005;131:208-213.
64. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21:270-276.
65. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33:313-320.
66. Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood. 2007;109:4105.
67. Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138:354-358.
68. Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109:2083-2088.
69. Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136:249-259.
70. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
71. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: WB Saunders;1995:166-194.
72. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood. 2006;108:2037-2040.
73. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood. 2006;108:2493-2494.
74. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132-1136.
75. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33-45.
76. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635-640.
77. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
78. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
79. Tefferi A, Mesa RA, Schroeder G, et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763-771.
80. Dingli D, Schwager SM, Mesa RA, et al. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia. Cancer. 2006;106:623-630.
81. Elliott M, Verstovsek S, Dingli D, et al. Absolute monocyte count is an independent prognostic factor for survival in agnogenic myeloid metaplasia. Leuk Res. In press.
82. Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia. 2007;21:1827-1828.
83. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158-1164.
84. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007;21:1858-1868.
85. Pardanani A, Lasho TL, Finke C, et al. Extending JAK2V617F and MPLW515 Mutation Analysis to Single Hematopoietic Colonies and B-and T-lymphocytes. Stem Cells. 2007;25:2358-2362.
86. Verstovsek S, Quintas-Cardama A, Kantarjian H, et al. Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs. 2006;15:1555-1563.
87. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108:1497-1503.